
SPRB Stock Forecast & Price Target
SPRB Analyst Ratings
Bulls say
Spruce Biosciences, Inc. is positioned favorably in the biopharmaceutical landscape due to its novel therapies targeting rare endocrine disorders, particularly with the promising product pipeline that includes Tralesinidase Alfa (TA-ERT), which demonstrates significant clinical benefits and a strong safety profile. The company is expected to capitalize on the growing CAH market and leverage enhanced diagnosis and awareness to drive the successful launch of TA-ERT, which has shown substantial evidence of normalizing heparan sulfate levels while correlating with improved cognitive outcomes in patients. Additionally, the strong commercial success of existing enzyme replacement therapies (ERTs) for similar conditions further bolsters confidence in Spruce’s market potential, supported by favorable five-year data indicating significant clinical and physiological benefits associated with TA-ERT.
Bears say
Spruce Biosciences faces a negative outlook primarily due to several financial and operational risks, including the potential failure to achieve commercial success with its lead product, Tralesinidase Alfa (TA-ERT), coupled with anticipated slower-than-expected market uptake amid substantial competition. The company remains in a development stage without any commercialized products, necessitating significant infrastructure investment to facilitate future launches while continuing to incur net losses until commercialization. Additionally, risks related to medium-term dilution emphasize cash management challenges, further complicating the company’s path to financial stability within a competitive biopharmaceutical landscape.
This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SPRB Analyst Forecast & Price Prediction
Start investing in SPRB
Order type
Buy in
Order amount
Est. shares
0 shares